Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
95.54
+1.79 (1.91%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Revvity Revenue
In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth. Revvity had revenue of $729.37M in the quarter ending December 29, 2024, with 4.81% growth.
Revenue (ttm)
$2.76B
Revenue Growth
+0.16%
P/S Ratio
4.09
Revenue / Employee
$250,457
Employees
11,000
Market Cap
11.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
RVTY News
- 15 days ago - Revvity to Hold Earnings Call on Monday, April 28, 2025 - Business Wire
- 16 days ago - Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery - Business Wire
- 16 days ago - Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Business Wire
- 4 weeks ago - Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - Business Wire
- 5 weeks ago - PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry - Business Wire
- 6 weeks ago - Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay - Business Wire
- 2 months ago - Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group - Business Wire
- 2 months ago - Revvity to Present at Upcoming Investor Conferences - Business Wire